99585-14-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-6-methyl-benzoic acid methyl ester is used as a chemical intermediate for the synthesis of various organic compounds, playing a crucial role in the development of new pharmaceuticals. Its stability and low toxicity make it a valuable component in drug formulation processes.
Used in Pesticide Production:
In the agricultural sector, 2-Chloro-6-methyl-benzoic acid methyl ester is employed as a building block in the creation of pesticides. Its chemical properties contribute to the effectiveness and safety of these products, ensuring their performance in protecting crops.
Used in Dye Manufacturing:
2-Chloro-6-methyl-benzoic acid methyl ester is also utilized in the dye industry, where it serves as a key component in the production of various dyes. Its chemical structure allows for the creation of dyes with specific color properties and stability.
Used in Chemical Product Development:
Beyond the aforementioned applications, 2-Chloro-6-methyl-benzoic acid methyl ester is a versatile building block in the broader chemical industry, contributing to the development of a wide array of products that require its unique properties for specific applications.

Upstream product

• 21327-86-6 2-chloro-6-methylbenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 89894-44-0 2-chloro-6-methylbenzoyl chloride 
• 201230-82-2 carbon monoxide 
• 5100-98-1 1-chloro-2-iodo-3-methylbenzene 
• 85070-46-8 2-chloro-6-methylbenzenediazonium tetrafluoroborate 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 89894-44-0 2-chloro-6-methylbenzoyl chloride 
• 116621-21-7 methyl 2-chloro-4-hydroxy-6-methylbenzoate 
• 482578-63-2 methyl 2-(bromomethyl)-6-chlorobenzoate 
• 21327-86-6 2-chloro-6-methylbenzoic acid 

Relevant academic research and scientific papers

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.

Substituted Spiro-amide Compounds

Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

Novel compounds useful for bradykinin B1 receptor antagonism

Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor.

PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S

The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R?2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.

ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to isoquinolinone derivatives and their use in modulating the activity of orphan nuclear receptors, pharmaceutical compositions containing such derivatives, and methods of using such derivatives in treating disease-states associ

COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF

Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1 6alkylthio, hydroxy, amino, mono or di C1 6alkylamino, an N-linked 4 to 7 memb

DIBENZOCYCLOHEPTENE COMPOUND

The present invention discloses a dibenzocycloheptene compound represented by the formula (I): ???wherein R1: hydrogen atom, halogen atom, etc., R2: hydrogen atom, halogen atom, etc., A: 5-membered or 6-membered heteroaromatic ring group containing 1 to 3 hetero atom(s) selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and the heteroaromatic ring group, etc. may have halogen atom, nitrogen atom, etc. as substituent(s), B: formula; -CH=CH-, formula; -CH2O-, etc., Y: C1-C10 alkylene group which may have halogen atom, etc. as substituent(s), etc., Z: carboxyl group which may be protected, etc., m: an integer of 1 to 4, n: an integer of 1 to 3, ???------ represents a single bond or a double bond, or a pharmaceutically acceptable salt thereof and a medical composition containing the same as an effective ingredient which has leukotriene C4 antagonistic action and leukotriene E4 antagonistic action in addition to potent leukotriene D4 antagonistic action, and useful as antiasthmatic agent, antiallergic agent and anti-inflammatory agent.

Two efficient methods for the preparation of 2-chloro-6-methylbenzoic acid

Two efficient methods for the preparation of 2-chloro-6-methylbenzoic acid were developed: one based on nucleophilic aromatic substitution and the other based on carbonylation. In the first approach, 2-chloro-6-fluorobenzaldehyde was converted to its n-butylimine, then treated with 2 equiv of methylmagnesium chloride in THF to give, after hydrolysis, 2-chloro-6-methylbenzaldehyde. Subsequent oxidation of this compound gave the title compound in 85% overall yield. In the second approach, 3-chloro-2-iodotoluene was efficiently carbonylated in methanol to give methyl 2-chloro-6-methylbenzoate, which after hydrolysis afforded the title compound in 94% yield (84% yield after recrystallization). The carbomethoxylation proceeded smoothly even at a high substrate-to-Pd ratio of 10 000. Both methods do not require isolation of intermediates and are suitable for the preparation of kilogram quantities of 2-chloro-6-methylbenzoic acid.